The renin-angiotensin-aldosterone system and glucose homeostasis

Trends in Pharmacological Sciences

Volumn 32, Issue 12, 2011, Pages 734-739

  Luther, James Matthew ^a   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BIGUANIDE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; LISINOPRIL; LOSARTAN; METFORMIN; OXPRENOATE POTASSIUM; PLACEBO; RAMIPRIL; RENIN; SPIRONOLACTONE; TROGLITAZONE; VALSARTAN;

B LYMPHOCYTE; CARDIOVASCULAR RISK; CONCENTRATION RESPONSE; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG INHIBITION; ENZYME ACTIVATION; GLUCOSE HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LYMPHOCYTE FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES MELLITUS; GLUCOSE METABOLISM DISORDERS; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MOLECULAR TARGETED THERAPY; OBESITY; RENIN-ANGIOTENSIN SYSTEM;

EID: 81755177460     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2011.07.006     Document Type: Review

References (64)

1. International Diabetes Federation Diabetes Atlas 3rd edn 2006 International Diabetes Federation
2. P. Hossain Obesity and diabetes in the developing world - a growing challenge N. Engl. J. Med. 356 2007 213 215 (Pubitemid 46143224)
3. S.M. Haffner Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N. Engl. J. Med. 339 1998 229 234 (Pubitemid 28350165)
4. M. Briet, and E.L. Schiffrin Aldosterone: effects on the kidney and cardiovascular system Nat. Rev. Nephrol. 6 2010 261 273
5. E.J. Lewis The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N. Engl. J. Med. 329 1993 1456 1462 (Pubitemid 23335891)
6. L. Husten Calcium antagonist stopped in ABCD study. Appropriate Blood Pressure Control in Diabetes Lancet 351 1998 731
7. B.M. Brenner Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N. Engl. J. Med. 345 2001 861 869
8. A.J. Scheen Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system Drugs 64 2004 2537 2565 (Pubitemid 39591650)
9. J.J. McMurray Effect of valsartan on the incidence of diabetes and cardiovascular events N. Engl. J. Med. 362 2010 1477 1490
10. S. Engeli The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int. J. Biochem. Cell Biol. 35 2003 807 825 (Pubitemid 36379323)
11. A.M. Sharma Angiotensin blockade prevents type 2 diabetes by formation of fat cells Hypertension 40 2002 609 611 (Pubitemid 35278594)
12. A.P. Rocchini Pathogenesis of weight-related changes in blood pressure in dogs Hypertension 13 1989 922 928 (Pubitemid 19157991)
13. T.L. Goodfriend Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans Hypertension 25 1995 30 36
14. M. Ehrhart-Bornstein Human adipocytes secrete mineralocorticoid-releasing factors Proc. Natl. Acad. Sci. U.S.A. 100 2003 14211 14216 (Pubitemid 37499216)
15. T.L. Goodfriend Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion Hypertension 43 2004 358 363 (Pubitemid 38174139)
16. S. Engeli Weight loss and the renin-angiotensin-aldosterone system Hypertension 45 2005 356 362 (Pubitemid 40315803)
17. C. Dall'Asta Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity Nutr. Metab. Cardiovasc. Dis. 19 2009 110 114
18. M.L. Tuck The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients N. Engl. J. Med. 304 1981 930 933 (Pubitemid 11101080)
19. The DREAM Trial Investigators Effect of ramipril on the incidence of diabetes N. Engl. J. Med. 355 2006 1551 1562
20. W.C. Knowler Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N. Engl. J. Med. 346 2002 393 403 (Pubitemid 34437694)
21. W.C. Knowler Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program Diabetes 54 2005 1150 1156 (Pubitemid 40446330)
22. DREAM (Diabetes reduction assessment with ramipril rosiglitazone) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial Lancet 368 2006 1096 1105
23. P.D. Home Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2009 2125 2135
24. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N. Engl. J. Med. 356 2007 2457 2471 (Pubitemid 46919772)
25. H.H. Parving Aliskiren combined with losartan in type 2 diabetes and nephropathy N. Engl. J. Med. 358 2008 2433 2446
26. S. Yusuf Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N. Engl. J. Med. 342 2000 145 153
27. M.A. Pfeffer Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N. Engl. J. Med. 349 2003 1893 1906 (Pubitemid 37409706)
28. L.A. Velloso Cross-talk between the insulin and angiotensin signaling systems Proc. Natl. Acad. Sci. U.S.A. 93 1996 12490 12495 (Pubitemid 26367171)
29. F. Folli Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk J. Clin. Invest. 100 1997 2158 2169 (Pubitemid 27500137)
30. F. Andreozzi Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells Circ. Res. 94 2004 1211 1218 (Pubitemid 38656407)
31. M.K. Diamond-Stanic, and E.J. Henriksen Direct inhibition by angiotensin II of insulin-dependent glucose transport activity in mammalian skeletal muscle involves a ROS-dependent mechanism Arch. Physiol Biochem. 116 2010 88 95
32. Y. Wei Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells J. Biol. Chem. 281 2006 35137 35146 (Pubitemid 46036553)
33. E.J. Henriksen Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats Hypertension 38 2001 884 890 (Pubitemid 34258687)
34. T. Shiuchi ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO Hypertension 40 2002 329 334 (Pubitemid 35006719)
35. M. Fujimoto An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes FEBS Lett. 576 2004 492 497 (Pubitemid 39388651)
36. C.C. Juan Angiotensin II enhances insulin sensitivity in vitro and in vivo Endocrinology 146 2005 2246 2254
37. M.C. Munoz Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats J. Hypertens. 27 2009 2409 2420
38. G. Lastra Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression Endocrinology 150 2009 2561 2568
39. Y.S. Kang Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice Nephrol. Dial. Transplant. 26 2011 1194 1204
40. T. Shiuchi Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice Hypertension 43 2004 1003 1010 (Pubitemid 38579905)
41. C.R. Carvalho Effect of captopril, losartan, and bradykinin on early steps of insulin action Diabetes 46 1997 1950 1957 (Pubitemid 27512079)
42. A. Csibi Angiotensin II inhibits insulin-stimulated GLUT4 translocation and Akt activation through tyrosine nitration-dependent mechanisms PLoS ONE 5 2010 e10070
43. G. Lastra Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat Am. J. Physiol. Endocrinol. Metab. 295 2008 E110 E116
44. A. Hirata Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice Cardiovasc. Res. 84 2009 164 172
45. T. Wada Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes Endocrinology 150 2009 1662 1669
46. D. Kraus Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes Horm. Metab. Res. 37 2005 455 459 (Pubitemid 41081228)
47. R. Urbanet Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism J. Clin. Endocrinol. Metab. 95 2010 4037 4042
48. S.E. Kahn Mechanisms linking obesity to insulin resistance and type 2 diabetes Nature 444 2006 840 846 (Pubitemid 46024990)
49. C. Weyer The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus J. Clin. Invest. 104 1999 787 794 (Pubitemid 29536364)
50. R. Saxena Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels Science 316 2007 1331 1336 (Pubitemid 46871653)
51. R. Sladek A genome-wide association study identifies novel risk loci for type 2 diabetes Nature 445 2007 881 885
52. P.S. Leung Pancreatic RAS Adv. Exp. Med. Biol. 690 2010 89 105
53. D. Fliser Angiotensin II affects basal, pulsatile, and glucose-stimulated insulin secretion in humans Hypertension 30 1997 1156 1161 (Pubitemid 27476173)
54. J.M. Luther Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets Diabetologia 54 2011 2152 2163
55. Y. Saitoh Candesartan attenuates fatty acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells Diabetes Res. Clin. Pract. 90 2010 54 59
56. L. Yuan Effects of renin-angiotensin system blockade on islet function in diabetic rats J. Endocrinol. Invest. 33 2010 13 19
57. M. Iwai Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice J. Hypertens. 28 2010 1471 1481
58. N.J. van der Zijl Valsartan improves β-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial Diabetes Care 34 2011 845 851
59. M.H. Weinberger Effects of eplerenone versus losartan in patients with low-renin hypertension Am. Heart J. 150 2005 426 433 (Pubitemid 41317608)
60. G. Sindelka Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment Exp. Clin. Endocrinol. Diabetes 108 2000 21 25 (Pubitemid 30160431)
61. K. Swaminathan Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles Diabetologia 51 2008 762 768
62. M. Yamaji Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(c) levels in patients with chronic heart failure Am. Heart J. 160 2010 915 921
63. Y. Arase Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C J. Med. Virol. 81 2009 1584 1590
64. R.S. McKelvie Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators Circulation 100 1999 1056 1064 (Pubitemid 29416231)